Natalizumab wearing-off symptoms: effect of extend interval dosing during Sars-CoV-2 pandemic.
End of dosing interval symptoms (EDIs)
Extended interval dosing (ExID)
Fatigue
Multiple sclerosis
Natalizumab wearing-off symptoms (WoS)
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
08
07
2022
accepted:
27
09
2022
revised:
26
09
2022
pubmed:
14
10
2022
medline:
2
2
2023
entrez:
13
10
2022
Statut:
ppublish
Résumé
Many patients treated with Natalizumab experience wearing-off symptoms (WoS) towards the end of the administration cycle. During the pandemic we advised and asked patients undergoing treatment with Natalizumab if they wanted to be shifted from a standard interval dosing (StID of 4 weeks) to an extended interval dosing (ExID of 5-6 weeks), regardless of their JCV index. Our main objective was to study prevalence and incidence of WoS when ExID was adopted. We enrolled 86 patients, from May 2020 to January 2021, evaluated at baseline and during a 6 months follow-up with a survey focused on WoS, Fatigue Severity Scale (FSS), Expanded Disability Status Scale (EDSS) and MRI. Among the 86 patients, 32 (37.2%) reported WoS. Most common one was fatigue (93.7%). Mean EDSS was higher in the group reporting WoS (3.8 WoS vs 3.1 non-WoS, p < 0.05). Sphincterial function was the EDSS item that significantly differed between the WoS group and the non-WoS group (1.4 WoS vs 0.6 non-WoS, p < 0.001). WoS correlate with the FSS scale (p < 0.001). Adopting an extended interval dosing does not result in significantly different occurrence of WoS between the ExID and the StID populations, in our cohort of patients. Interestingly, there is a strong correlation between WoS and a higher EDSS and FSS. Safety and efficacy of Natalizumab with ExID are relatively preserved in our study.
Sections du résumé
BACKGROUND
BACKGROUND
Many patients treated with Natalizumab experience wearing-off symptoms (WoS) towards the end of the administration cycle. During the pandemic we advised and asked patients undergoing treatment with Natalizumab if they wanted to be shifted from a standard interval dosing (StID of 4 weeks) to an extended interval dosing (ExID of 5-6 weeks), regardless of their JCV index. Our main objective was to study prevalence and incidence of WoS when ExID was adopted.
METHODS
METHODS
We enrolled 86 patients, from May 2020 to January 2021, evaluated at baseline and during a 6 months follow-up with a survey focused on WoS, Fatigue Severity Scale (FSS), Expanded Disability Status Scale (EDSS) and MRI.
RESULTS
RESULTS
Among the 86 patients, 32 (37.2%) reported WoS. Most common one was fatigue (93.7%). Mean EDSS was higher in the group reporting WoS (3.8 WoS vs 3.1 non-WoS, p < 0.05). Sphincterial function was the EDSS item that significantly differed between the WoS group and the non-WoS group (1.4 WoS vs 0.6 non-WoS, p < 0.001). WoS correlate with the FSS scale (p < 0.001).
CONCLUSION
CONCLUSIONS
Adopting an extended interval dosing does not result in significantly different occurrence of WoS between the ExID and the StID populations, in our cohort of patients. Interestingly, there is a strong correlation between WoS and a higher EDSS and FSS. Safety and efficacy of Natalizumab with ExID are relatively preserved in our study.
Identifiants
pubmed: 36229702
doi: 10.1007/s00415-022-11408-0
pii: 10.1007/s00415-022-11408-0
pmc: PMC9559546
doi:
Substances chimiques
Natalizumab
0
Immunologic Factors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
595-600Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Références
Rudick RA, Stuart WH, Calabresi PA et al (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354:911–923
doi: 10.1056/NEJMoa044396
Sehr T, Proschmann U, Thomas K et al (2016) New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies. J Neuroinflammation 13:164
doi: 10.1186/s12974-016-0635-2
Rudick RA, Sandrock A (2004) Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev Neurother 4:571–580
doi: 10.1586/14737175.4.4.571
Khatri BO, Man S, Giovannoni G et al (2009) Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 72:402–409
doi: 10.1212/01.wnl.0000341766.59028.9d
Clerico M, De Mercanti SF, Signori A et al (2020) Extending the interval of natalizumab dosing: is efficacy preserved? Neurother J Am Soc Exp Neurother 17:200–207
Zhovtis Ryerson L, Frohman TC, Foley J et al (2016) Extended interval dosing of natalizumab in multiple sclerosis. J Neurol Neurosurg Psychiatry 87:885–889
doi: 10.1136/jnnp-2015-312940
Bomprezzi R, Pawate S (2014) Extended interval dosing of natalizumab: a two-center, 7-year experience. Ther Adv Neurol Disord 7:227–231
doi: 10.1177/1756285614540224
Cathérine D, Annelien P, Anne S et al (2020) End of dose interval symptoms in patients treated with natalizumab: a role for serum cytokines? Mult Scler Relat Disord 41:102020
doi: 10.1016/j.msard.2020.102020
Ratchford JN, Brock-Simmons R, Augsburger A et al (2014) Multiple sclerosis symptom recrudescence at the end of the natalizumab dosing cycle. Int J MS Care 16:92–98
doi: 10.7224/1537-2073.2013-017
Foley JF, Stuve O (2020) Natalizumab wearing-off effect: the hunt for the elusive pharmacodynamic biomarker. Neurol Neuroimmunol Neuroinflamm 7(3):e706
doi: 10.1212/NXI.0000000000000706
Beckerman H, Eijssen IC, van Meeteren J, Verhulsdonck MC, de Groot V (2020) Fatigue profiles in patients with multiple sclerosis are based on severity of fatigue and not on dimensions of fatigue. Sci Rep 10:4167
doi: 10.1038/s41598-020-61076-1
Wattjes MP, Rovira À, Miller D et al (2015) MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients. Nat Rev Neurol 11:597–606
doi: 10.1038/nrneurol.2015.157
Montalban X, Gold R, Thompson AJ et al (2018) ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler (Houndmills, Basingstoke, England) 24:96–120
doi: 10.1177/1352458517751049
Bringeland GH, Myhr K-M, Vedeler CA, Gavasso S (2020) Wearing-off at the end of natalizumab dosing interval and risk of MS disease activity: a prospective 1-year follow-up study. J Neurol Sci 415:116880
doi: 10.1016/j.jns.2020.116880
Riancho J, Setien S, de la Torre JRS et al (2021) Does extended interval dosing natalizumab preserve effectiveness in multiple sclerosis? A 7 year-retrospective observational study. Front Immunol 12:614715
doi: 10.3389/fimmu.2021.614715
Ryerson LZ, Foley J, Chang I et al (2019) Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology 93:e1452–e1462
Bringeland GH, Blaser N, Myhr KM, Vedeler CA, Gavasso S (2021) Wearing-off symptoms during standard and extended natalizumab dosing intervals: Experiences from the COVID-19 pandemic. J Neurol Sci 429:117622
doi: 10.1016/j.jns.2021.117622
van Kempen ZLE, Doesburg D, Dekker I et al (2019) The natalizumab wearing-off effect: end of natalizumab cycle, recurrence of MS symptoms. Neurology 93:e1579–e1586
Mowry EM, Bourdette D (2019) Natalizumab wearing-off symptoms: Patients with MS on extended interval dosing may not “mind the gap.” Neurology 93:735–736
doi: 10.1212/WNL.0000000000008358
Vaughn CB, Kavak KS, Dwyer MG et al (2020) Fatigue at enrollment predicts EDSS worsening in the New York State Multiple Sclerosis Consortium. Mult Scler J 26:99–108
doi: 10.1177/1352458518816619
Morrow SA, Conway D, Fuchs T et al (2021) Quantifying cognition and fatigue to enhance the sensitivity of the EDSS during relapses. Mult Scler (Houndmills, Basingstoke, England) 27:1077–1087
doi: 10.1177/1352458520973618
Nazari F, Shaygannejad V, Mohammadi Sichani M, Mansourian M, Hajhashemi V (2020) Quality of life among patients with multiple sclerosis and voiding dysfunction: a cross-sectional study. BMC Urol 20:62
doi: 10.1186/s12894-020-00590-w
Bringeland GH, Blaser N, Myhr K-M, Vedeler CA, Gavasso S (2020) Wearing-off at the end of natalizumab dosing intervals is associated with low receptor occupancy. Neurol Neuroimmunol Neuroinflamm 7:e678
doi: 10.1212/NXI.0000000000000678
Puñet-Ortiz J, Hervás-García JV, Teniente-Serra A et al (2018) Monitoring CD49d receptor occupancy: a method to optimize and personalize natalizumab therapy in multiple sclerosis patients. Cytom B Clin Cytom 94:327–333
doi: 10.1002/cyto.b.21527
Foley JF, Goelz S, Hoyt T, Christensen A, Metzger RR (2019) Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing. Mult Scler Relat Disord 31:65–71
doi: 10.1016/j.msard.2019.03.017
Tanaka M, Kinoshita M, Foley JF, Tanaka K, Kira J, Carroll WM (2015) Body weight-based natalizumab treatment in adult patients with multiple sclerosis. J Neurol 262:781–782
doi: 10.1007/s00415-015-7655-1
Fisk JD, Pontefract A, Ritvo PG, Archibald CJ, Murray TJ (1994) The impact of fatigue on patients with multiple sclerosis. Can J Neurol Sci (Le journal canadien des sciences neurologiques) 21:9–14
doi: 10.1017/S0317167100048691
Bakshi R, Shaikh ZA, Miletich RS et al (2000) Fatigue in multiple sclerosis and its relationship to depression and neurologic disability. Mult Scler (Houndmills, Basingstoke, England) 6:181–185
doi: 10.1177/135245850000600308
Bergamaschi R, Romani A, Versino M, Poli R, Cosi V (1997) Clinical aspects of fatigue in multiple sclerosis. Funct Neurol 12:247–251